SBI net profit up 67% in Q2, chairman says asset quality significantly improved, BFSI News, ET BFSI

[ad_1]

Read More/Less


The State Bank of India, India’s largest lender, today reported a standalone net profit of Rs 7,626 crore, up 67% on year, the highest ever for the bank.

A year ago, the bank reported a net profit of Rs 4,574 crore. On a sequential basis, the profit rose 17% from Rs 6,504 crore in the June quarter.

The bank’s asset quality has significantly improved, chairman Dinesh Khara said at the earnings announcement.

Gross non performing assets came in at 4.90% in the September quarter, lower than 5.32% in the June quarter and 5.28% in the year ago quarter.

Meanwhile, the net NPA ratio stood at 1.52% for the quarter.

The net interest income (NII) – the difference between interest earned and expended – rose 10.6% to Rs 31,184 crore in Jul-Sep.

The non interest income fell 3.7% to Rs 8,207 crore compared with Rs 8,527 crore a year ago.

Khara highlighted that the capacity utilisation of manufacturing is still very low. Advances rose by just 6.17% over last year, driven by personal retail advances, up 15.17% on year, and foreign office advances, up 16.18% on year.

Domestic advances grew 4.61%, with home loans, which constitute 24% of domestic advances, rising 10.74% on year.

Total deposits grew nearly 10% on year, current account deposits grew 19.2% and saving bank deposits grew 10.55%.



[ad_2]

CLICK HERE TO APPLY

RBI panel spells out norms to streamline functioning of ARCs

[ad_1]

Read More/Less


The performance of asset reconstruction companies (ARCs) in management of stressed assets of banks/financial institutions (FIs) since inception in 2003 is still uneven on several parameters, according to a Reserve Bank of India’s Committee to Review the Working of Asset Reconstruction Companies.

Overall recovery made by the ARC sector during FY04-FY13 was 68.6 per cent when measured in terms of redemption of Security Receipts (SRs), which are issued by ARCs as part of securitisation of assets acquired, as a percentage of total SRs issued, the report said.

However, the same comes down to 14.29 per cent when the redemption is measured in terms of the book value of the assets acquired.

RBI panel favours sale of stressed assets by lenders at early stage

“This implies that banks and other investors could recover only about 14 per cent of the amount owed by their borrowers,” the committee headed by Sudarshan Sen, former Executive Director, RBI, said.

The total SRs issued reflects the cost of acquisition for the ARCs vis-à-vis the book value of such financial assets. Redemption of SRs is a proxy for the amount recovered from these accounts.

ARCs are required to resolve the assets within a maximum of eight years of acquisition of financial assets and redeem the SRs representing the assets. Therefore, the period after FY13 has SRs for which resolution is still underway.

Winds of change in the stressed assets market

Business revival

The committee observed that ARCs’ performance in ensuring revival of businesses has also been poor. The data indicate that approximately 80 per cent of the recovery for the sector, so far, has come through deployment of methods of reconstruction that do not necessarily lead to revival of business.

“ARCs have rarely used methods such as change in or takeover of the management of the business of the borrower or conversion of debt into equity in a borrower’s company,” the panel said.

Rescheduling of payment of debts was also involved only in 19.9 per cent of the recovery made by ARCs.

The committee underscored “The overall performance of ARC Sector has left much to be desired. However, it would be incorrect to assume that the problems of ARC sector are entirely of its own making. In fact, the ageing of NPAs before their sale may be contributing to poor recovery. This gets further aggravated by lack of debt aggregation.”

Revival of stressed business typically requires additional funding which is difficult to come by for old NPAs.

“Inadequate capital at ARC level and the regulatory prescription limiting the extent of funds that could be raised, from external investors through securitisation, seems to have made ARCs’ attempt at revival of businesses even more difficult. ARCs’ lack of skill sets in turning around borrowers cannot be ignored,” the committee said.

The panel emphasised that despite the reshaping of the ecosystem available for lenders for handling of stressed assets and the ARC sector’s sub-optimal performance and its challenges, the ARC model remains relevant as a private sector led permanent institutional framework for out-of-court resolution of stressed assets of the financial sector.

[ad_2]

CLICK HERE TO APPLY

2 Pharma Stocks To Buy From ICICI Securities

[ad_1]

Read More/Less


Ajanta Pharma

Ajanta Pharma’s today’s share price is Rs. 2085 per share on November 3, till 2.00 PM IST. ICICI Securities has given a target price of Rs. 2500 per share with a target period of 12 months for the stock.

The company is a focused player in branded, which constitutes ~70% of overall sales. Till FY21 their overall exports: domestic formulations ratio was at 70:30. Ajanta Pharma’ in Q2FY22 reports a strong number, which was ahead of estimates on their sales front. Their sales were up 23.6% YoY to Rs. 884.8 crore. Ajanta’s PAT grew 15.1% YoY to Rs. 195.9 crore.

According to ICICI Securities, “Ajanta’s share price has grown by ~1.4x over the past 5 years (from ~ Rs. 1502 in June 2016 to ~ Rs. 2126 levels in October 2021). We retain our BUY rating on the stock with a focused approach. We value Ajanta at Rs. 2500 i.e. 30x P/E on FY23E EPS.”

Additionally, the brokerage firm said, Ajanta’s “Q2 results were driven by growth across segments amid some dip in gross margin performance. The management expects to maintain domestic growth momentum in FY22 leveraging on the already launched products. On the EBITDA margins front, the management expects to maintain the current rate in FY22. Overall, calculated focus, steady gross margins, and lighter balance sheet are some key differentiators for Ajanta, going ahead.”

Sun Pharmaceutical Industries (SUNPHA)

Sun Pharmaceutical Industries (SUNPHA)

Sun Pharmaceutical Industries (SUNPHA) is having a share price of Rs. 786.55 on November 3, till 2.10 PM IST. ICICI Securities has identified it as a stock to buy. ICICI Securities has given a target price of Rs. 965 with a Target Period of 12 months for this company’s stock.

ICICI informs, “Sun Pharma is world’s fourth-largest specialty generic company with sales of US$3.8 billion and boasts of 43 manufacturing sites addressing segments, like specialty products, branded generics, complex generics, pure generics and APIs.” Sun Pharma has a market share of 8.2%, and the company is ranked No. 1 in domestic formulations while enjoying a leadership position in 11 specialties based on prescription.

In Q2FY22 Sun Pharma reports strong Q2FY22 results, their sales were up 12.5% YoY to Rs. 9625.9 crore and EBITDA was at Rs. 2629.9 crore, which was up 19.9% YoY with margins at 27.3%. Additionally, their consequent adjusted PAT stood at Rs. 2047 crore that increased by 12.9% YoY.

According to ICICI Securities, “Sun Pharma’s share price has increased by ~1.06x over the past 5 years (from ~ Rs. 763 in June 2016 to ~Rs. 815 levels in October 2021). We change our rating from HOLD to BUY due to more consistency on the specialty front and linear growth trajectory India formulations. Higher contribution from specialty and the strong domestic franchise is likely to change the product mix towards more remunerative businesses by FY23.”

Disclaimer

Disclaimer

The above stocks were from the brokerage report of ICICI Direct. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution. Greynium Information Technologies, the author, and the brokerage house are not liable for any losses caused as a result of decisions based on the article.



[ad_2]

CLICK HERE TO APPLY

U GRO Capital Q2 net profit down 80%

[ad_1]

Read More/Less


U GRO Capital reported an 80 per cent drop in its net profit for the second quarter of the fiscal at ₹3.37 crore compared to ₹17.17 crore in the same period last fiscal.

For the quarter ended September 30, 2021, its total revenue jumped up by 80.1 per cent to ₹62.7 crore from ₹34.82 crore a year ago.

Net interest income for the second quarter of the fiscal increased by 53 per cent to ₹31.7 crore compared to ₹20.7 crore in the second quarter of last fiscal.

Net interest margin improved 40 basis points Q-o-Q to 7.7 per cent largely due to reduction in the borrowing cost, U GRO Capital said in a statement on Wednesday.

However, total expenses also shot up by 80.1 per cent on a year-on-year basis to ₹57.98 crore in the second quarter of the fiscal.

The total provisioning as of September 2021 was ₹24.2 crore versus the regulatory requirement of ₹22.1 crore.

Disbursements for the quarter grew 139 per cent sequentially to ₹790 crore.

“The company clocked its highest ever disbursements in September 2021 at ₹288 crore,” it added.

“We will carry on the momentum and traction which is now coming because of the infrastructure we have built over last one year and we have a clear path of achieving our mission of serving 10 lakh customers and take one per cent market share of outstanding MSME credit in the country,” said Shachindra Nath, Executive Chairman and Managing Director of U GRO Capital.

[ad_2]

CLICK HERE TO APPLY

IBC needs a stronger push: Crisil

[ad_1]

Read More/Less


The Insolvency and Bankruptcy Code (IBC) needs a stronger push after recovery of about ₹2.5 lakh crore over five years since it took effect, according to Crisil Ratings.

From here, reforms must stress quicker resolution and maximise recovery, the credit rating agency said in a study.

Per the agency: “A closer look at the data shows, however, the recovery rate and resolution timelines have a lot more room for improvement.

“This makes a continuous strengthening of the Code and stabilisation of the overall ecosystem imperative.”

Lesser traction

As of June 30, 2021, IBC had enabled recovery of about ₹2.5 lakh crore, against admitted financial claims of about ₹7 lakh crore, translating to a recovery rate of 36 per cent for the 396 cases resolved out of the total 4,541 admitted.

Of the remaining cases, 1,349 were under liquidation; 1,114 were closed under appeal/ review/ settled or withdrawn, and 1,682 were outstanding.

The agency emphasised that the recovery marks a significant shift in the insolvency resolution process and credit culture in India.

Gurpreet Chhatwal, Managing Director, Crisil Ratings, said: “The recent resolution of a large financial services firm with a recovery of about ₹37,000 crore against admitted financial claim of about ₹87,000 crore, translating to a recovery rate of about 43 per cent, underscores the efficacy of IBC. The resolution value was about 1.4 times the liquidation value.”

The agency underscored that while the IBC has tilted the power equation in favour of creditors from debtors and helped strengthen India’s insolvency resolution ecosystem, its performance against its twin objectives – maximisation of recovery and timebound resolution – has been a mixed bag.

“One, only a few large cases have seen higher recovery. Excluding the top 15 cases (by resolution value) from the 396 resolved cases, the recovery rate halves to 18 per cent.

“Two, average resolution time for the aforementioned resolved cases is 419 days compared with the stipulated maximum of 330 days. About 75 per cen of outstanding cases have already been pending for more than 270 days,” the study said.

Liquidation: a challenge

Nitesh Jain, Director, Crisil Ratings, noted that besides low recovery rate and longer timeframe, a key challenge is the high number of cases going to liquidation.

“As of June 30, 2021, nearly one-third of the 4,541 admitted cases had gone into liquidation, with a recovery rate estimated at merely 5 per cent.

“That said, around three-fourths of these cases were either sick or defunct. With closure of these vintage cases, recovery rate as well as timelines are expected to improve,”he said.

Notwithstanding these challenges, the IBC has played a key role in resolution of stressed assets so far, according to the study.

“Its effectiveness will continue to be tested given the elevated level of stressed assets in the Indian financial system,” it added.

[ad_2]

CLICK HERE TO APPLY

Credit Suisse to tighten the reins after string of scandals, BFSI News, ET BFSI

[ad_1]

Read More/Less


Credit Suisse will unveil a new centralised structure on Thursday in an attempt to bring its far-flung divisions to heel and draw a line under a string of scandals that have cost the Swiss bank billions of dollars, two sources said.

Over the past year, Credit Suisse has been fined for arranging a fraudulent loan to Mozambique, tarnished by its involvement with defunct financier Greensill, racked up $5.5 billion in losses when U.S. family office Archegos collapsed, and been rebuked by regulators for spying on executives.

Credit Suisse drafted in seasoned banker Antonio Horta-Osorio as chairman in April to stop the rot and he will lay out his charter to reform Switzerland‘s second-biggest bank on Thursday when it presents third-quarter results.

One key change is expected to be the creation of a single wealth management division that caters to a global elite, centralising oversight at the bank’s headquarters in Zurich, two people familiar with the matter told Reuters.

Under the current structure put in place six years ago, wealth management straddles three divisions: a Swiss business, an Asia-Pacific arm catering mainly to rich Chinese and an international arm based out of Switzerland.

Merging the wealth division would make Credit Suisse simpler and potentially pave the way for cost cuts.

It would also rein in local bankers who have enjoyed much autonomy, making them more answerable to senior managers who have often been blindsided by the risks that triggered past scandals, the sources said.

One of the people told Reuters that managers at the bank’s headquarters had become very risk averse and they did not want to give leeway to local bankers, regardless of how much profit they were making.

A spokesman for Credit Suisse declined to comment.

SHARES SUFFER

Credit Suisse’s financial humiliation stands in stark contrast to its cross-town rival UBS.

In the wake of massive losses and a bailout during the financial crisis, UBS successfully pivoted away from investment banking to wealth management and is now the world’s largest wealth manager with $3.2 trillion in invested assets.

Its shares have climbed 57% in the past 10 years while Credit Suisse has slumped 53% over the same period.

Shareholders have deserted Credit Suisse this year following the slew of bad headlines. Its shares are down 12% while UBS is up 36% while Wall Street rivals are riding high on the back of a boom in equity trading and M&A.

Andreas Venditti, an analyst at Swiss private bank Vontobel, said it would take more than “minor changes and a new divisional set-up” at Credit Suisse to reverse the trend.

The expected revamp at Credit Suisse has also encouraged some high-profile dealmakers to approach the bank’s senior management to suggest it merges with a rival, another person with knowledge of the matter said.

Those ideas have been rejected so far, however, the person said.

Nonetheless, the prospect of a challenge by investors demanding the break-up of the bank, or that its shrinking market value makes it a target for a hostile foreign takeover, have long troubled managers, sources told Reuters earlier this year.

‘WARNING SIGNALS’

With a market value of $28 billion, Credit Suisse is worth less than half of UBS and a fraction of Wall Street giants such as JPMorgan weighing in at half a trillion dollars.

But an approach from the United States would not go down well in Switzerland. Relations between Swiss banks and Washington were damaged when the United States pressured them into giving up their strict secrecy code more than a decade ago.

A combination of Credit Suisse and UBS, which has been touted as an alternative alliance, would face its own problems. For one, it would dominate the Swiss market.

Another source said that while Credit Suisse had examined a sale or spin-off of its asset management business, that had been shelved. The person said, however, that once further efforts were made to cut costs and boost growth, a sale, or listing of the business on the market, could be back on the cards.

The bank’s drive to centralise its operations is drawing on lessons from some of its recent failures, including Archegos.

Earlier this year, Credit Suisse published a report blaming a focus on maximizing short-term profits and enabling “voracious risk-taking” by Archegos for failing to steer the bank away from catastrophe.

Despite long-running discussions about Archegos – by far the bank’s largest hedge fund client – Credit Suisse’s top management were apparently unaware of the risks it was taking.

The bank’s chief risk officer and the head of its investment bank recall hearing about it first only on the eve of the fund’s collapse.

“There were numerous warning signals,” the report said. “Yet the business … failed to heed these signs.”



[ad_2]

CLICK HERE TO APPLY

Credit card spends jump 60% in September, set for further festive push, BFSI News, ET BFSI

[ad_1]

Read More/Less


Another option, if you are unable to make payments by the due date, is opting for a loan against your credit card. Various credit card companies offer pre-approved loans to customers, these can actually come in handy in this scenario. However, be mindful of the costs as the interest rate and other charges may be steeper. If you have multiple credit cards, compare interest rates and processing fees on each and go with the one that has least total cost for your preferred loan tenure.

Credit card spends jumped 60 per cent year-on-year (YoY) in September, helped by the onset of the festive season.

On a sequential basis, the growth slowed down to 3 per cent at Rs 80,500 crore, according to various research reports.

The festive season, opening up of the economy and rising consumer confidence is set to keep the credit card spends buoyant, experts say.

Kotak Mahindra Bank reported the highest growth (27% MoM) in September, followed by IndusInd Bank and ICICI Bank (13% each). Other major players reported growth in the +-4% range. On a two-year CAGR basis, spends for ICICI Bank grew 58%, IndusInd 33%, Kotak Mahindra Bank 29%. HDFC Bank and SBI Cards posted growth of 10–15% and Axis Bank and SCB 2–3%. While, Citi and Amex saw a decline of 8% and 26%, respectively. ICICI Bank surpassed SBI Cards to become the second-largest player in spends, with market share of 19.3% over 6MFY22.

Outstanding credit cards up 10.8%

The total number of outstanding credit cards in the system grew 10.8% YoY to 65 million in September 2021 – the highest in the past 11 months.

Among the major players, ICICI Bank reported strong growth of 26.1% YoY, followed by IndusInd Bank (15.6%), SBI Cards (14.3%). Foreign players such as American and Citi witnessed declines of 10% and 5% respectively. SBI Cards and ICICI Bank continued to perform strongly, resulting in a 59–218 bps YoY increase in market share to 19.3% and 18.0% respectively in September.

ICICI Bank added close to 2 million new cards in the past 10 months, taking its credit card base to 11.6 million as of September.

Despite a 247 bps year on year decline, HDFC Bank remained the largest player with a market share of 23.0%.

10.91 lakh card adds

Around 10.91 lakh new cards were added to the system in September with HDFC Bank being the largest acquirer at 2.44 lakh cards. ICICI Bank added 2.34 lakh, Axis Bank added 2.03 lakh, while SBI Cards added 1.75 lakh cards in September, while, Standard Chartered Bank, AMEX and Citi posted a decline of 13,000, 11,000 and 4,500, respectively, in the card base. IDFCF Bank also posted a strong performance with 39,000 new credit card additions in September.

Higher spends per card

Monthly spends per card for the industry increased to Rs 12400, from an average of Rs 10,700 over the past six months (higher v/s pre-Covid levels). This was attributable to an increase in the ticket size to Rs 4,300, the highest in the past several years.

Conversely, the number of transactions per card declined to 2.8 v/s 3.0 in August (3.1 in March). IndusInd and Kotak Mahindra Bank saw a higher increase of Rs 2,400 and Rs 2,200, respectively, followed by ICICI Bank with Rs 1,400.

IndusInd (Rs 9,700) and Amex (Rs 5,900) had the highest ticket sizes, followed by Kotak Mahindra Bank (Rs 5,100) and ICICI Bank (Rs4,900). All other players were in the range of Rs 3,900–Rs 4,300 – barring Citi and SCB, which were lower at Rs 3,000–3,200.



[ad_2]

CLICK HERE TO APPLY

Reserve Bank of India – Tenders

[ad_1]

Read More/Less


Reserve Bank of India, Archives intends to prepare a panel of suppliers for supply of archival preservative material (archival stationery) to RBI Archives, College of Agricultural Banking (CAB), Reserve Bank of India, Pune. The panel is expected to remain operational for a period three years from the date of empanelment subject to satisfactory performance.

The expected annual procurement is ₹4.0 Lakh (Rupees Four lakh only) which may be increased or decreased at the sole discretion of the Bank.

Interested suppliers may visit the Bank’s web-site https://www.rbi.org.in for full details and for downloading the application form. The last date for submission of duly completed application form is December 01, 2021 up to 02:00 P.M.

The Bank reserves the right to reject any or all of the applications without assigning any reason thereof.

Chief Archivist

[ad_2]

CLICK HERE TO APPLY

2 Stocks To “BUY” For Good Gains Up To 28% In 1 Year: ICICI Direct

[ad_1]

Read More/Less


Buy Trent Ltd with a target price of Rs 1330

Trent is India’s top retailer, with 400+ outlets and a footprint in a variety of consumer sectors. According to the brokerage, Trent reported its highest ever quarterly revenue in Q2FY22, followed by robust EBITDA margins. On a favourable base, revenue grew 126% YoY to Rs 1020.4 crore (two-year CAGR: 12%). “Trent also reported robust EBITDA margins of 21.7% (Q2FY21: 1.4%, Q2FY20: 16.2%). On account of robust operational performance, PAT came in at Rs 125.6 crore (Q2FY20: Rs 38.3 crore, Q2FY21: (-) Rs 48.1 crore)” the brokerage said.

“Trent has been an exceptional performer with stock price appreciating at ~39% CAGR in the last five years. We value Trent at Rs 1330 based on SOTP valuation” said ICICIdirect.

ICICIdirect has said “During its recent AGM, the management has affirmed its aggressive store opening plans for its fashion format (Westside: 35 & Zudio: 75) in FY22 (outlined CAPEX worth Rs 200 crore in FY22E). Capex trajectory accelerated in H1FY22 with CAPEX up 224% YoY to Rs 68.7 crore. Trent continues to have healthy cash and investments worth Rs 685 crore, which would enable it to tide over the current situation better than peers. We maintain BUY rating on the stock with a revised target price of Rs 1330 (earlier | 1100).”

Buy Dabur India with a target price of Rs 745

Buy Dabur India with a target price of Rs 745

Dabur India Ltd is a prominent FMCG company in India, with revenues of over Rs 7,680 crore and a market cap of over Rs 48,800 crore. “Dabur reported healthy results with 10% volume growth, sales were up 12% YoY with strong growth across segments, EBITDA was at Rs 620.7 crore, up 9% YoY, with margins at 22% and consequent PAT was at Rs 505.3 crore (up 4.6% YoY)” said the brokerage.

“Dabur’s share price has given 100% return in the last five years (from Rs 298 in November 2016 to Rs 598 in November 2021). We maintain our estimates with expected strong growth propelled through new product, rural distribution & Ayurveda, naturals consumption tailwind. We value the stock at Rs 745 on ascribing 55x FY24 earnings multiple. We continue to maintain our BUY rating on the stock” ICICIdirect has said.

Disclaimer

Disclaimer

The above stocks are picked from the brokerage report of ICICI Direct. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution. Greynium Information Technologies, the author, and the brokerage house are not liable for any losses caused as a result of decisions based on the article.



[ad_2]

CLICK HERE TO APPLY

1 126 127 128 129 130 16,278